Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II cabazitaxel in pre-treated metastatic non-seminomatous germ-cell tumors
2013-000286-36Phase 2Active
- Sponsor
- Gustave Roussy
- Start
- Jan 2014
- Modality
- Allosteric Modulators → Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of cabazitaxel in non-seminomatous germ cell tumor (NSGCT) and germ cell tumor (GCT), sponsored by Gustave Roussy. Primary endpoint: Favorable response rate. Started Jan 2014; status: active.
02
Drugs
cabazitaxel
03
Conditions
non-seminomatous germ cell tumor (NSGCT)germ cell tumor (GCT)
Beyond the preview
Go deeper on 2013-000286-36.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2013-000286-36.